Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy M Goodwin

Showing results (221-230 of 258) with videos related to

Pageof 26
Sort By:
The Journal of Clinical Psychiatry|June 6, 2009
Treatment nonadherence and neurocognitive impairment in bipolar disorderAnabel Martinez-Aran, Jan Scott, Francesc Colom, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 16, 2011
Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disordersThomas C Baghai, Pierre Blier, David S Baldwin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 3, 2016
Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulateDarragh Downey, Arpan Dutta, Shane McKie, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2023
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medicationGuy M Goodwin, Megan Croal, David Feifel, et al.
Neuroscience Applied|July 14, 2025
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspectsDrummond E-Wen McCulloch, Matthias E Liechti, Kim Pc Kuypers, et al.
International Journal of Bipolar Disorders|July 22, 2023
The IBER study: a feasibility randomised controlled trial of imagery based emotion regulation for the treatment of anxiety in bipolar disorderCraig Steel, Kim Wright, Guy M Goodwin, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 6, 2011
Safety of antipsychotics in people with intellectual disabilityValeria Frighi, Matthew T Stephenson, Alireza Morovat, et al.
The Journal of Clinical Psychiatry|March 6, 2025
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive DisorderGuy M Goodwin, Ania Nowakowska, Merve Atli, et al.
Psychopharmacology|August 22, 2023
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processingRobert F Dougherty, Patrick Clarke, Merve Atli, et al.
Journal of Behavior Therapy and Experimental Psychiatry|September 20, 2020
Feasibility and efficacy of a digital CBT intervention for symptoms of Generalized Anxiety Disorder: A randomized multiple-baseline studyChristopher B Miller, Jenny Gu, Alasdair L Henry, et al.
Pageof 26

Showing results (221-230 of 258) with videos related to

Sort By:
Pageof 26
The Journal of Clinical Psychiatry|June 6, 2009
Treatment nonadherence and neurocognitive impairment in bipolar disorderAnabel Martinez-Aran, Jan Scott, Francesc Colom, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 16, 2011
Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disordersThomas C Baghai, Pierre Blier, David S Baldwin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 3, 2016
Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulateDarragh Downey, Arpan Dutta, Shane McKie, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2023
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medicationGuy M Goodwin, Megan Croal, David Feifel, et al.
Neuroscience Applied|July 14, 2025
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspectsDrummond E-Wen McCulloch, Matthias E Liechti, Kim Pc Kuypers, et al.
International Journal of Bipolar Disorders|July 22, 2023
The IBER study: a feasibility randomised controlled trial of imagery based emotion regulation for the treatment of anxiety in bipolar disorderCraig Steel, Kim Wright, Guy M Goodwin, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 6, 2011
Safety of antipsychotics in people with intellectual disabilityValeria Frighi, Matthew T Stephenson, Alireza Morovat, et al.
The Journal of Clinical Psychiatry|March 6, 2025
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive DisorderGuy M Goodwin, Ania Nowakowska, Merve Atli, et al.
Psychopharmacology|August 22, 2023
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processingRobert F Dougherty, Patrick Clarke, Merve Atli, et al.
Journal of Behavior Therapy and Experimental Psychiatry|September 20, 2020
Feasibility and efficacy of a digital CBT intervention for symptoms of Generalized Anxiety Disorder: A randomized multiple-baseline studyChristopher B Miller, Jenny Gu, Alasdair L Henry, et al.
Pageof 26